Benign Prostatic Hyperplasia
Conditions
Brief summary
The objectives of the trial are to demonstrate the safety and performance of the Zenflow Spring System in relieving the symptoms of obstructive Benign Prostatic Hyperplasia (BPH).
Detailed description
A multi-center, prospective, single arm safety and performance trial. Subjects will be treated either in the Investigator's out-patient treatment room or in the OR, with local anaesthesia only. All subjects will be followed for the entire duration of the study until exit after the 60 month follow-up visit.
Interventions
DEVICEZenflow Spring System
The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
Sponsors
Zenflow, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Multi-center, prospective, single-arm.
Eligibility
Sex/Gender
MALE
Age
45 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient is able and willing to comply with all the assessments of the study 2. Patient or patient's legal representative has been informed of the nature of the study, agrees to participate and has signed the informed consent form 3. ≥ 45 years of age 4. Baseline IPSS score \> 13, and a baseline Quality of Life (QoL) question score \> 3 5. Prostate volume 25 - 80 cc by Trans Rectal Ultrasound (TRUS) or abdominal ultrasound, measured within past 90 days and prostatic urethral length between 2.5- 4.5 cm 6. Failed, intolerant, or patient choice to not take a medication regimen for the treatment of LUTS 7. Patient must meet ONE of the following criteria: 1. Baseline PSA \<= 2.5ng/mL 2. Baseline PSA \>2.5 ng/mL and \<=10 ng/mL AND free PSA \>=25% of total PSA (no biopsy required or negative biopsy) 3. Baseline PSA \>10ng/mL AND negative prostate biopsy1 result within 12 months 4. Negative prostate biopsy1 within 12 months if abnormal digital rectal examination 5. 3 Tesla MRI of the prostate, with normal findings, within 12 months prior to the baseline visit
Exclusion criteria
1. Obstructive intravesical median prostatic lobe which, in the opinion of the Investigator, would not benefit from treatment 2. Urethral stricture, meatal stenosis, or bladder neck obstruction - either current, or recurrent requiring 2 or more dilations as reported in the patient's history 3. Requiring self-catheterization to void 4. Baseline PSA \> 10 ng/mL or confirmed or suspected prostate cancer 5. Any of the following, taken from a single uroflowmetry reading: 1. Peak urinary flow rate \> 12 ml/second 2. Post-void residual (PVR) \> 250 ml 3. Peak Urinary flow rate of \> 15 ml/second 4. \< 125ml urinary volume voided at baseline (pre-bladder urinary volume of ≥ 150 ml required) 6. Other condition or disease that might cause urinary retention 7. History of other diseases causing voiding dysfunction 8. Concomitant Urinary Tract Infection (UTI) (subject can be enrolled following successful treatment of UTI and a clean urine test), or a history of recurrent or chronic UTIs (defined as 2 or more UTIs in the past 12 months) 9. Concomitant bladder stones 10. Previous pelvic irradiation or radical pelvic surgery 11. Previous prostate surgery, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate 12. Chronic prostatitis, or recurring prostatitis within the past 12 months 13. Known allergy to nickel 14. Life expectancy less than 24 months 15. Use of concomitant medications (e.g., anticholinergics, antispasmodics or antidepressants) affecting bladder function 16. Inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure (low dose aspirin therapy not prohibited) 17. Taking 5-alpha reductase inhibitors within 3 months of pre-treatment (baseline) evaluation unless evidence of same drug dose for at least 6 months with a stable voiding pattern (the drug dose should not be altered or discontinued throughout the study) 18. Taking one of the following within 2 weeks of pre-treatment (baseline) evaluation: 1. alpha-blockers, 2. androgens, 3. anticholinergics, or 4. cholinergic medication gonadotropin releasing hormonal analogs 19. Taking one of the following within 24 hours of pre-treatment (baseline) evaluation: 1. phenylephrine, or 2. pseudoephedrine 20. Future fertility concerns 21. Any severe illness that might prevent study completion or would confound study results
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Need for urinary catheterization | 7 days after the procedure | Rate of extended post-operative urinary catheterization |
| Successful placement of the Zenflow Spring Implant | Day of discharge up to 7 days following device placement | Successful deployment and procedural success for the Zenflow System to implant the Spring device in the operating room or an out-patient clinical setting. |
| Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH) using the International Prostate Symptom Score and Quality of Life Score (IPSS+QoL) | Baseline and 3 months | The patient is asked to respond to 7 questions related to his urinary health using a rating scale of 0 to 5 where zero is excellent and 5 is the worst possible. The responses to the 7 questions are tallied for a total score. In addition the patient is asked 1 question related to his Quality of Life. The possible responses range from 0 to 6 where 0 is the best and 6 is the worst. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of Pain, evaluated using a Visual Analog Score (VAS) of 1 to 10 | Baseline, 2 weeks, 1 month and 3 months | Patient describes pain on a Visual Analog Scale (VAS). The scale is a line labeled 1 at the far left indicating minimal pain and 10 on the right, which is maximum pain. |
| Incidence of procedure or device related serious adverse events | Up to 30 days | Assessment of any device or procedure related Serious Adverse Events (SAE) |
| Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH) | Baseline, 2 weeks, 1, 6, 12, 24 months | The patient is asked to respond to 7 questions related to his urinary health using a rating scale of 0 to 5 where zero is excellent and 5 is the worst possible. The responses to the 7 questions are tallied for a total score. In addition the patient is asked 1 question related to his Quality of Life. The possible responses range from 0 to 6 where 0 is the best and 6 is the worst. |
| Assessment of Adverse Events | Up to 2 years | Rate of adverse events related to the procedure or device. |
| Assessment of Sexual Health Assessment: Change in sexual health measured by change in the Sexual Health Inventory for Men (SHIM) questionnaire score | Baseline, 3, 6, 12, & 24 months | The patient selects the most appropriate response to 5 questions about his sexual health. Each response has an assigned value between 1 and 5. The numeric values are tallied for a total score. |
| Assessment of Sexual Health Assessment: Change in sexual health measured by change in ability to ejaculate using the Male Sexual Health Questionnaire - Ejaculatory domain (MSHQ-EjD) | Baseline, 3, 6, 12, & 24 months | The patient selects the most appropriate response to 4 questions about his sexual health specific to ejaculation. Each response has an assigned value between 0 and 5. |
Countries
Australia, New Zealand
Contacts
Primary ContactDebra Cogan, B.A., RN
Backup ContactNicholas Damiano, MS
Outcome results
None listed